Retrophin Revenue and Competitors

We are a biopharmaceutical company (RTRX) dedicated to identifying, developing and delivering life-changing therapies to people living with rare diseases. With our promising pipeline, commercial portfolio and more than 180 team members worldwide, we are a thriving and patient-centric company striving to become a leader in the rare disease community. Giving patients a chance and providing hope is what drives us. Our number one priority will always be the patients we serve. Our approach centers on our pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including a joint development arrangement evaluating the potential of CNSA-001 in phenylketonuria (PKU), a rare genetic metabolic condition that can lead to neurological and behavioral impairment. Our R&D efforts are supported by growing revenues from our portfolio of three commercial products. Thank you for visiting our LinkedIn profile. Please read our community guidelines to understand how we manage our social media engagement: retrophin.com/community-guidelines

keywords:Biotechnology, Healthcare